Table 1. Vaccine constructs, doses, and times of immunization.

Vaccine	Trial	Group (n)	Particle units (pu) per dose			# doses	Total dose (pu)
			CSP	AMA1	Total
NMRC-M3V-Ad-PfCA(CSP & AMA1 mixed)	1	1 (6)	1×1010	1×1010	2×1010	1	2×1010
		2 (6)	5×1010	5×1010	1×1011	1	1×1011
NMRC-MV-Ad-PfC(CSP only)	2	3 (15)	1×1010	0	1×1010	2	2×1010

Trial 1: Dose escalation study: Group 1 was immunized with a single dose, a safety review was conducted, then Group 2 was immunized with a single five-fold higher dose.

Trial 2: Challenge study. Group 3 was immunized twice using the Group 1 dose of CSP, with 16 weeks between doses. Fifteen volunteers received the first dose, 14 volunteers the second, and 12 volunteers underwent malaria challenge 21 days following the second immunization. Data from Trial 2 are presented in the companion paper, Tamminga et al.